STAT3 and B-cell chronic lymphocytic leukemia: The relationship of increased NFκB activation with decreased STAT3 phosphorylation caused by ruxolitinib (Figure 2D) suggested JAK-activating cytokines in the cultures might be inhibiting TLR-signaling in CLL cells.